Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Inflammation-based Index as a Predictive Marker of Clinical and Radiological Response in Patients Treated With Lu-177 Oxodotreotide for Intestinal Neuroendocrine Tumour

NCT06876532 is registered in ClinicalTrials.gov with Institut Claudius Regaud as lead sponsor.

NCT NCT06876532
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06876532 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Inflammation-based Index as a Predictive Marker of Clinical and Radiological Response in Patients Treated With Lu-177 Oxodotreotide for Intestinal Neuroendocrine Tumour
Lead sponsor
Institut Claudius Regaud
Phase
Not applicable
Overall status
Recruiting
Start date
April 7, 2025
Completion date
April 30, 2031
Enrollment
150 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

intestinal neuroendocrine tumor